Indication intelligence, analysis and sector perception

The Biostage Chronicles: dispose and disregard, fit for the barrel

January 11, 2022 5:42pm

Old news as regurgitated, in a recent press release “New Paper Shows Biostage's Esophageal Implant Regenerates the Esophagus in Piglets” on 1/10.

For the record, BSTG CAN’T treat birth defects in the esophagus in babies until they complete trials from a two (2) year old IND which have yet to start.

Dr. Christine Finck, Surgeon in Chief, Connecticut Children's Medical Center is NOT an independent investigator, she is paid through a grant awarded to BSTG and is also a share and option holder as a member of their scientific board. Also as stated, “Connecticut Children's Medical Center is also an investor in Biostage.”

Should/would investors trust BSTG as they continue to operate under a “cloud” after their insurance company rejected their claim for reimbursement of legal fees and terminal death suit costs? They are also DESPARATE to raise money to operate and reduce possible personal liabilities of management and those they had indemnified?

Monday - “Pumping and promoting” up and away was Biostage (BSTG) which jumped to $3.23 with 1,760 shares traded early in the session then dropping -$0.03 with 2,076 shares traded sliding to $2.33.

Tuesday - “Pumping and promoting” up, up and away as Biostage (BSTG) jumped +$0.87 to $3.20 with 7,089 shares traded (3-month average = 1979 shares)

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

2 hours 46 min ago
RegMed Investors (RMi) Closing Bell: hammered

11 hours 37 min ago
RegMed Investors’ (RMi) pre-open: expectation versus reality

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.